Operators, scientists, and clinicians who have built oncology programs before.

Brett Lanier is a medicinal chemist with over 20 years of experience in the pharmaceutical industry and founder of Isosceles Pharmaceuticals. He has completed the Harvard Business School Private Equity and Venture Capital program, and he is the inventor on several patent filings. His background includes extensive knowledge around chemical synthesis and pharmaceutical-scale GMP manufacturing.

He has worked within the medical device, clinical research, and pharmaceutical contract manufacturing industries with branded and 505(b)(2) branded generic customers at all levels of drug development, from pre-formulation through early and late phase trials and commercial launch post FDA approval.

Drawing on his almost 20 years of experience in the pharmaceutical industry, Dr. Neuman provides expertise in medical affairs, new product development, launch strategies, pharmacovigilance, and business development. Board-certified in Internal Medicine, Dr. Neuman still practices medicine on a part-time basis.

During his pharmaceutical career, he held senior executive positions including Vice President of Global Regulatory Affairs, Vice President of Medical Affairs, and Chief Medical Officer for a Fortune 500 global healthcare company. Across these roles he successfully led efforts to gain regulatory approval and clinician acceptance of multiple products, including pharmaceuticals, medical devices, and imaging diagnostics.

Deborah Mosca is a proven leader of multi-disciplinary drug development teams with the ability to anticipate risks and implement creative solutions to meet project timelines and budgets. She has guided the discovery and development of novel therapeutic agents for human, animal, and agricultural applications across biotech, non-profit research institutions, and large pharma.

As Chairman and Chief Executive Officer of the Marine Bio-Technologies Center of Innovation, she created the business strategy to commercialize marine biotechnologies from North Carolina's network of premier marine research institutions. At PaxVax, she provided strategic leadership for vaccine development programs and supported revenue generation through contracts, licensing, corporate partnerships, and venture capital activities. While at The Scripps Research Institute, Deborah coordinated efforts for the IBM-TSRI Consortium for Project Checkmate (a proactive approach to avian flu) and joined Governor Jeb Bush in meetings with Roche and Novartis to stimulate international economic development in Florida.

Mark Mannebach has over 30 years of experience in the pharmaceutical industry in Regulatory Affairs, with extensive knowledge of Quality Assurance, Program Management, and Pharmaceutical Science. During his career he has filed numerous NDAs, BLAs, PMEs, ANDAs, and 505(b)(2) submissions.

Mark has supported the development of branded and specialty pharmaceuticals as well as biologics across many therapeutic applications, including ophthalmology, pain management, neurology and CNS, and anti-inflammation.

Nathaniel Hernandez is a scientist specializing in quality data analysis and clinical drug development. With over a decade of award-winning experience in scientific communication, he has successfully engaged diverse audiences through both in-person and digital platforms. As a pharmacology researcher, Nathaniel has developed expertise in cancer, endocrinology, and central nervous system disorders, and his doctoral dissertation explores the therapeutic potential of a novel gene therapy for chronic primary pain conditions.

He is also experienced in pharmaceutical strategy, having enhanced product pipelines and supported investigator-initiated studies for a large pharmaceutical company. Certified in medical and regulatory affairs, Nathaniel contributes to the missions of innovative healthcare and biotechnology companies.

Dr. Sam Fagg is a translational research scientist at the University of Texas Medical Branch, where his lab investigates RNA processing, antisense oligonucleotide therapeutics, and regenerative biologics across oncology, immunology, and tissue repair. He earned his PhD in MCD Biology from UC Santa Cruz and has served as Principal Investigator on NIH and industry-funded programs, including the development of antisense oligonucleotides designed to enhance soluble IL-7R as a novel cancer immunotherapy approach.

His published work spans peer-reviewed studies on tissue regeneration, wound healing, and RNA-mediated regulation of immune signaling, with research output appearing in journals such as Stem Cells Translational Medicine and the International Wound Journal. Dr. Fagg brings to Isosceles deep expertise in mechanistic translational science and immunotherapy target discovery.

Tim Wright is a highly accomplished executive with a 30-year track record of building, transforming, and positioning pharmaceutical organizations for continued growth across highly competitive markets. A visionary, focused leader recognized for creating value and improving quality of life, Tim leverages extensive experience in pain management and inflammatory diseases. He has led full-lifecycle development of novel therapeutic modalities, from conception through commercialization and growth across North America, Europe, and Asia.

Robert Stein, a Duke University Graduate School alumnus, has wide-ranging expertise across drug discovery, clinical research, development, and clinical trials in biopharmaceuticals and oncology. He served as Executive Director and Head of Pharmacology at Merck Sharp & Dohme, SVP of R&D and CSO at Ligand Pharmaceuticals, and EVP of Research & Pre-Clinical Development at DuPont-Merck Pharmaceuticals.

Robert also served as President of Incyte and Roche, CEO of KineMed, Inc., Senior Advisor of R&D at Agenus, Inc., and is currently an Operating Partner at Samsara BioCapital.

Devin Bosch founded Capital Group in 2004, a successful business strategy and venture firm. With over 50 liquidity-driven events, Capital Group became internationally recognized with multiple offices in San Francisco, the Bay Area, and Charlotte, NC. In 2008, he co-founded Nuwa Ventures, a family office located in Walnut Creek, CA.

Kevin Fickle is an entrepreneur with extensive capital markets experience in the technology and consumer goods verticals. He has worked at multiple private equity firms, where he held responsibilities including overseeing the operational strategy and capital markets activities of his funds' portfolio companies.

In 2008, he co-founded Nuwa Ventures, a family office, where he is responsible for originating, structuring, and analyzing portfolio investments and has served as its President since founding. Mr. Fickle received a B.S. in Finance from San Diego State University.

Michael A. Caligiuri, MD is the former President of City of Hope National Medical Center in Los Angeles, where he held the Deana and Steve Campbell Physician-in-Chief Distinguished Chair. He continues to lead his laboratory at City of Hope as a professor of Hematology and Hematopoietic Cell Transplantation.

Before City of Hope, Dr. Caligiuri served as CEO of The Ohio State University James Cancer Hospital and Director of OSU's Comprehensive Cancer Center, where he oversaw the construction of one of the largest cancer hospitals in the U.S. with over 300 faculty.

A nationally recognized cancer immunology expert, Dr. Caligiuri is a member of the National Academy of Medicine, a Fellow of the AACR Academy and AAAS, and a past president of the AACR. He has received the NCI MERIT Award, NCI Outstanding Investigator Award, and Stanford School of Medicine's Achievement Award.

Gil Bashe has dedicated his career to advancing health, innovation, and access, from his early experience as a combat medic in an elite paratrooper unit to advising leaders in the boardroom. He serves as Chair of Global Health and Purpose at FINN Partners, where he helps organizations connect science, medicine, and advocacy with the people they serve. His leadership spans top roles across leading communications firms and global health organizations, shaping strategies at the intersection of policy, innovation, and public trust.

A trusted advisor in high-stakes environments, Gil is widely recognized for guiding organizations through complex regulatory, litigation, and reputation challenges, particularly in the pharmaceutical and life sciences sectors. He serves on multiple advisory boards, including the American Diabetes Association and Marfan Foundation, and has earned numerous industry honors for his influence in health innovation and communications. He is also the author of the forthcoming book Healing the Sick Care System, Why People Matter.

Michael Giuliani is a 30+ year drug development physician with over one hundred new market authorizations for eighteen different products spread across 60 countries. He was involved in the development of multiple FDA-approved pain therapies and anti-inflammatory drugs, including Zipsor, Diclofenac 1.5/2.0%, Exalgo, Xartemis XR, Topiramate, Neurontin, Pregabalin, and a generic Fentanyl Transdermal System (FTS) Patch.

His positions have included Chief Medical Officer at Xanodyne Pharmaceuticals, Head of R&D at Mallinckrodt Pharmaceuticals, and roles at Merck, Wyeth, and Covidien. Dr. Giuliani has authored dozens of peer-reviewed scientific publications, chapters, and abstracts, and has led due diligence, licensing, out-licensing, and investor interaction activities at Merck, Xanodyne, Covidien, and Mallinckrodt.

Mr. Harrison is Chairman Emeritus of the Diversified Agency Services (DAS) division of Omnicom Group, having served as its President, then Chairman and CEO.

He co-founded The Harrison & Star Business Group, comprising companies in healthcare, medical education, and healthcare public relations that represented many of the largest and best-known pharmaceutical and biotech companies. Mr. Harrison currently serves on a number of prestigious boards as a Fellow of the New York Academy of Medicine and member of the New York Academy of Sciences.

He is a recipient of the Ellis Island Medal of Honor and holds an Honorary Doctorate from West Virginia University, where he earned a graduate degree in cell biology and physiology.

Hunter Land is Vice President, Translational Research at Biopharmaceutical Research Company and an Executive Board Member at Alterola Biotech, Inc. He has more than 20 years of R&D expertise spanning 25 different indications, and has built a track record of advancing novel small molecules from discovery into clinical development.

Hunter has co-authored multiple clinical protocols across refractory epilepsy (Dravet Syndrome and Lennox-Gastaut Syndrome), multiple sclerosis, and pain. He has been a speaker at over 50 scientific conferences, is a named inventor on 6 patent applications, has more than 20 publications, and is a guest lecturer at the University of Wisconsin and Colorado State University. He serves as Senior Scientific Advisor for the NHL Alumni / NEEKA Brain Health initiative.

Mike Royal is a senior pharmaceutical executive with over 30 years of experience in the drug development process, with expertise in clinical research and medical and regulatory affairs. He has overseen clinical trials from Phase 1 through Phase 4, including multi-site and multi-country studies, and has an established track record of innovative solutions to development obstacles.

Mike has been instrumental in setting product launch and lifecycle management strategies and has successfully submitted NCE and 505(b)(2) NDAs across several indications, as well as ANDAs. He is board-certified in internal medicine, anesthesiology, pain management, and addiction medicine, and has authored over 190 peer-reviewed publications, book chapters, and abstracts.